3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
1
Resectable Non-small Cell Lung Cancer
1
Ovarian Neoplasms
1
Nonsquamous Non-small Cell Lung Cancer
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Interventions
Leucovorin
22
Fluorouracil
22
Gemcitabine
21
Capecitabine
21
Paclitaxel
20
Docetaxel
20
Irinotecan
15
Carboplatin
15
Radiosurgery
14
Oxaliplatin
13
Cisplatin
13
Bevacizumab
13
Zoledronic Acid
12
pembrolizumab
11
Radiotherapy
11
Fulvestrant
11
palbociclib
9
Pemetrexed
9
Drug Therapy
9
130-nm albumin-bound paclitaxel
9
Surgical Procedures, Operative
7
Letrozole
7
Ibandronic Acid
7
abemaciclib
6
Trastuzumab
6
Prednisone
6
Vinorelbine
5
Folfox protocol
5
Floxuridine
5
Doxorubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm Metastasis
×
Platinum Compounds
×
Clear all
NCT06216301
2025-12-17
LUNAR-2
NovoCure Ltd.
Phase 3
Recruiting
734 enrolled